Literature DB >> 16272284

Critical requirement of CD11b (Mac-1) on T cells and accessory cells for development of experimental autoimmune encephalomyelitis.

Daniel C Bullard1, Xianzhen Hu, Trenton R Schoeb, Robert C Axtell, Chander Raman, Scott R Barnum.   

Abstract

Mac-1 (CD18/CD11b) is a member of the beta2-integrin family of adhesion molecules and is implicated in the development of many inflammatory diseases. The role of Mac-1 in the development of CNS demyelinating diseases, including multiple sclerosis, is not understood, and Ab inhibition studies in experimental allergic encephalomyelitis (EAE), the animal model for multiple sclerosis, have produced conflicting findings. To clarify these results and to determine Mac-1-mediated mechanisms in EAE, we performed EAE using Mac-1-deficient mice. Mac-1 homozygous-deficient, but not Mac-1 heterozygous-deficient mice, had significantly delayed onset and attenuated EAE. Leukocyte infiltration was similar in both groups of mice in early disease but significantly reduced in spinal cords of receptor-deficient mice in late disease. Adoptive transfer of Ag-restimulated T cells from wild-type to Mac-1-deficient mice produced significantly attenuated EAE, whereas transfer of Mac-1-deficient Ag-restimulated T cells to control mice failed to induce EAE. T cells from myelin oligodendrocyte glycoprotein (MOG)35-55 peptide-primed Mac-1-deficient mice displayed an altered cytokine phenotype with elevated levels of TGF-beta and IL-10, but reduced levels of IL-2, IFN-gamma, TNF-alpha, IL-12, and IL-4 compared with control mice. Mac-1-deficient T cells from primed mice proliferated comparably to that of control T cells on MOG35-55 restimulation in vitro. However, the draining lymph nodes of MAC-1-deficient mice on day 10 after MOG35-55 immunization contained lower frequency of blast T cells than in control mice, suggesting poor priming. Our results indicate that Mac-1 expression is critical on both phagocytic cells and T cells for the development of demyelinating disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272284     DOI: 10.4049/jimmunol.175.10.6327

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease.

Authors:  Alexander J Szalai; Xianzhen Hu; Jillian E Adams; Scott R Barnum
Journal:  Mol Immunol       Date:  2007-03-13       Impact factor: 4.407

2.  Disruption of the beta2-integrin CD11d (alphaDbeta2) gene fails to protect against experimental autoimmune encephalomyelitis.

Authors:  Jillian E Adams; Matthew S Webb; Xianchen Hu; Don Staunton; Scott R Barnum
Journal:  J Neuroimmunol       Date:  2007-01-23       Impact factor: 3.478

Review 3.  Leukocytes in glomerular injury.

Authors:  Stephen R Holdsworth; Peter G Tipping
Journal:  Semin Immunopathol       Date:  2007-10-16       Impact factor: 9.623

4.  Peripheral dendritic cells are essential for both the innate and adaptive antiviral immune responses in the central nervous system.

Authors:  Christina D Steel; Suzanne M Hahto; Richard P Ciavarra
Journal:  Virology       Date:  2009-03-04       Impact factor: 3.616

Review 5.  Role of microglia in neuronal degeneration and regeneration.

Authors:  Lisa Walter; Harald Neumann
Journal:  Semin Immunopathol       Date:  2009-09-09       Impact factor: 9.623

Review 6.  Genetics of SLE: evidence from mouse models.

Authors:  Laurence Morel
Journal:  Nat Rev Rheumatol       Date:  2010-05-04       Impact factor: 20.543

Review 7.  beta2-integrins in demyelinating disease: not adhering to the paradigm.

Authors:  Xianzhen Hu; Jillian E Wohler; Kari J Dugger; Scott R Barnum
Journal:  J Leukoc Biol       Date:  2009-12-09       Impact factor: 4.962

8.  Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation.

Authors:  L L Santos; A Dacumos; J Yamana; L Sharma; E F Morand
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

9.  Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.

Authors:  Xianzhen Hu; Stephen Tomlinson; Scott R Barnum
Journal:  Neurosci Lett       Date:  2012-10-16       Impact factor: 3.046

Review 10.  The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.

Authors:  Jessy John Alexander; Aileen Judith Anderson; Scott Robert Barnum; Beth Stevens; Andrea Joan Tenner
Journal:  J Neurochem       Date:  2008-10-24       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.